PMID: 18184535Jan 11, 2008Paper

Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man

International Journal of Clinical Pharmacology and Therapeutics
Dietrich TuerckSilke Appel-Dingemanse

Abstract

The d-isomer of methylphenidate (d-MPH) is the pharmacologically active part of the racemic mixture of methylphenidate (d,l-MPH), which has been used for decades in the treatment of attention-deficit/hyperactivity disorder (ADHD). A modified release formulation with bimodal release for the pure d-enantiomer (Focalin XR) has been developed to enable a fast onset of action and a sustained activity for once-daily administration. It was intended to achieve a bimodal concentration-time profile as observed after administration of two immediate release Focalin tablets. The pharmacokinetics of this d-MPH bimodal release formulation were compared with a d-MPH immediate release formulation and a similar bimodal release formulation of d,l-MPH in healthy adult volunteers. 25 volunteers received a single 20 mg dose of d-MPH bimodal release formulation, two 10 mg doses of a d-MPH immediate release formulation given 4 h apart and a single 40 mg dose of d,l-MPH bimodal release formulation (1 : 1 ratio for d : l enantiomers). The washout between treatments in this 3-way crossover study was 7 days. All three formulations were well-tolerated at the doses tested. The d-MPH bimodal release formulation generated two distinct d-MPH plasma concentrati...Continue Reading

Citations

May 27, 2011·Neuroscience Bulletin·Normand Carrey, Michael Wilkinson
Oct 30, 2012·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Kennerly S PatrickRobert J Malcolm
Nov 26, 2011·Expert Review of Clinical Pharmacology·Josephine EliaKarin Borgmann-Winter
Aug 19, 2007·Journal of Pharmaceutical Sciences·Joanne C Severs, Wayne A Froland
May 25, 2010·Current Medical Research and Opinion·Matthew BramsFrank A López
Oct 11, 2014·Journal of Pharmaceutical Sciences·Kennerly S PatrickCristina E Murphy
Jun 26, 2007·Journal of Colloid and Interface Science·Moran Wang, Shiyi Chen
Dec 4, 2008·Human Psychopharmacology·Kennerly S PatrickMario A González
Jan 13, 2015·Disasters·Ruoxi Lu, Rebekka M Dudensing
Nov 1, 2011·Drug Metabolism and Disposition : the Biological Fate of Chemicals·James C ErmerRichard C Page
Oct 5, 2019·Expert Opinion on Drug Metabolism & Toxicology·Ann C ChildressF Randy Sallee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.